首页> 中文期刊> 《中外医疗》 >高通血液透析联合超纯水透析在尿毒症患者微炎症防治中的临床应用

高通血液透析联合超纯水透析在尿毒症患者微炎症防治中的临床应用

         

摘要

Objective To explore the high-flux hemodialysis with ultrapure water used in dialysis patients with uremia for joint microinflammation impact. Methods Convenient select uremic patients in 2013 — 2015 admitted to 80 cases in, ac-cording to randomized double-blind divided into two groups, with 40 patients in the control group:Super Joint control group on the basis of: conventional therapy + high flux hemodialysis, the observation group pure dialysis were compared microin-flammatory improvement (hCRP, β2-MG and IL-6 and TNF-α). Results After treatment microinflammatory indicators are improved, and the effect is significant (P<0.05), between the two groups, the observation group better [hCRP: control group:(15.4 ± 3.2), (11.3 ± 1.7); observation group :(15.2 ± 3.7), (3.7 ± 0.0). β2-MG: control group: (26.5 ± 6.5),(18.3 ± 3.0); ob-servation group: (25.6 ± 6.2), (6.6 ± 1.3)], the difference was significant (P<0.05). Conclusion To be high-flux hemodialy-sis patients with uremia combined with super-pure water dialysis treatment for improving the effect of micro-inflammation worthy of recognition and clinical reference.%目的:探究高通量血液透析与超纯水透析联合应用于尿毒症患者对于微炎症的影响。方法方便选取2013—2015年收治的尿毒症患者80例,按照随机双盲法原则分成两组,各40例,对照组:常规治疗+高通量血液透析,观察组:对照组基础上联合超纯水透析,比较两组微炎症改善情况(hCRP、β2-MG以及IL-6和TNF-α)。结果治疗后微炎症指标均改善,且效果显著(P﹤0.05),组间比较,观察组效果更佳[hCRP:对照组:(15.4±3.2)、(11.3±1.7);观察组:(15.2±3.7)、(3.7±0.0)。β2-MG:对照组:(26.5±6.5)、(18.3±3.0);观察组:(25.6±6.2)、(6.6±1.3)],差异有统计学意义(P﹤0.05)。结论予以尿毒症患者高通量血液透析联合超纯水透析治疗,对于微炎症的改善效果值得肯定和临床参考。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号